Literature DB >> 22569194

Heterogeneity of cholinergic denervation in Parkinson's disease without dementia.

Nicolaas I Bohnen1, Martijn L T M Müller, Vikas Kotagal, Robert A Koeppe, Michael R Kilbourn, Sid Gilman, Roger L Albin, Kirk A Frey.   

Abstract

Parkinson's disease (PD) is a multisystem neurodegenerative disorder. Heterogeneous clinical features may reflect heterogeneous changes in different brain regions. In contrast to the pronounced nigrostriatal denervation characteristic of PD, cholinergic changes are less marked. We investigated cholinergic innervation activity in PD subjects relative to normal subjects. Nondemented PD subjects (n=101, age 65.3±7.2 years) and normal subjects (n=29, age 66.8±10.9 years) underwent clinical assessment and [(11)C]methyl-4-piperidinyl propionate acetylcholinesterase and [(11)C]dihydrotetrabenazine monoaminergic positron emission tomography (PET) imaging. Cholinergic projection changes were heterogeneous for 65 out of 101 PD subjects who had neocortical and thalamic acetylcholinesterase activity within the normal range. The remainder had combined neocortical and thalamic (13/101), isolated neocortical (18/101), or isolated thalamic (5/101) acetylcholinesterase activity below the normal range. The low neocortical acetylcholinesterase activity subgroup had significantly lower global cognitive performance compared with the normal range subgroup (F=7.64, P=0.0069) with an independent effect for nigrostriatal denervation (F=7.60, P=0.0074). The low thalamic acetylcholinesterase activity subgroup did not differ from the normal thalamic acetylcholinesterase activity subgroup in cognitive performance or motor impairments except for a history of falls (P=0.0023). Cholinergic denervation is heterogeneous with reduced neocortical and/or thalamic acetylcholinesterase activity in 36% of nondemented PD subjects with corresponding clinical phenotypic variation. Results also show independent cognitive effects for both cholinergic and dopaminergic system changes in nondemented PD subjects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569194      PMCID: PMC3421100          DOI: 10.1038/jcbfm.2012.60

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  37 in total

1.  Changes in motor subtype and risk for incident dementia in Parkinson's disease.

Authors:  Guido Alves; Jan Petter Larsen; Murat Emre; Tore Wentzel-Larsen; Dag Aarsland
Journal:  Mov Disord       Date:  2006-08       Impact factor: 10.338

2.  Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype.

Authors:  J-P Taylor; E N Rowan; D Lett; J T O'Brien; I G McKeith; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-06-27       Impact factor: 10.154

3.  Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.

Authors:  R Hilker; A V Thomas; J C Klein; S Weisenbach; E Kalbe; L Burghaus; A H Jacobs; K Herholz; W D Heiss
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

4.  Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; G M Constantine; Ch A Mathis; J G Davis; R Y Moore; S T Dekosky
Journal:  J Neurol       Date:  2005-09-02       Impact factor: 4.849

5.  Impaired attention predicts falling in Parkinson's disease.

Authors:  L M Allcock; E N Rowan; I N Steen; K Wesnes; R A Kenny; D J Burn
Journal:  Parkinsonism Relat Disord       Date:  2008-05-19       Impact factor: 4.891

6.  Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

Authors:  H Shimada; S Hirano; H Shinotoh; A Aotsuka; K Sato; N Tanaka; T Ota; M Asahina; K Fukushi; S Kuwabara; T Hattori; T Suhara; T Irie
Journal:  Neurology       Date:  2009-05-27       Impact factor: 9.910

7.  History of falls in Parkinson disease is associated with reduced cholinergic activity.

Authors:  N I Bohnen; M L T M Müller; R A Koeppe; S A Studenski; M A Kilbourn; K A Frey; R L Albin
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

8.  Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

Authors:  D Aarsland; K Brønnick; J P Larsen; O B Tysnes; G Alves
Journal:  Neurology       Date:  2008-11-19       Impact factor: 9.910

9.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Authors:  Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

10.  Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.

Authors:  Caroline H Williams-Gray; Adam Hampshire; Roger A Barker; Adrian M Owen
Journal:  Brain       Date:  2008-01-04       Impact factor: 13.501

View more
  82 in total

1.  Clinical markers for identifying cholinergic deficits in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen; Vikas Kotagal; Peter J H Scott; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Complex Movement Control in a Rat Model of Parkinsonian Falls: Bidirectional Control by Striatal Cholinergic Interneurons.

Authors:  Cassandra Avila; Aaron Kucinski; Martin Sarter
Journal:  J Neurosci       Date:  2020-06-18       Impact factor: 6.167

3.  Neuroimaging and clinical predictors of fatigue in Parkinson disease.

Authors:  Kelvin L Chou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Parkinsonism Relat Disord       Date:  2015-12-02       Impact factor: 4.891

4.  Mentally stimulating activities associate with better cognitive performance in Parkinson disease.

Authors:  Jeffrey L B Bohnen; Martijn L T M Müller; Jacob Haugen; Nicolaas I Bohnen
Journal:  J Neural Transm (Vienna)       Date:  2017-07-19       Impact factor: 3.575

5.  Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.

Authors:  Ajeesh Koshy Cherian; Aaron Kucinski; Ryan Wu; Inge E M de Jong; Martin Sarter
Journal:  Psychopharmacology (Berl)       Date:  2019-01-04       Impact factor: 4.530

Review 6.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

7.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

Review 8.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

Review 9.  Reassessment of the role of the central cholinergic system.

Authors:  Anna Hrabovska; Eric Krejci
Journal:  J Mol Neurosci       Date:  2013-11-10       Impact factor: 3.444

10.  Cholinergic Oculomotor Nucleus Activity Is Induced by REM Sleep Deprivation Negatively Impacting on Cognition.

Authors:  Patrícia Dos Santos; Adriano D S Targa; Ana Carolina D Noseda; Lais S Rodrigues; Juliane Fagotti; Marcelo M S Lima
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.